Anika Therapeutics commenced EU launch of CINGAL®, its third-generation viscosupplement, to treat osteoarthritis-related pain. The product is slated for initial availability in the Czech Republic, Germany, Hungary, Italy and Poland, to be marketed by various commercial partners.
CINGAL received CE Mark approval for the present application in 1Q16.
In addition to Europe, CINGAL is available in Canada. Anika continues to pursue U.S. regulatory approval of the product.
Anika Therapeutics commenced EU launch of CINGAL®, its third-generation viscosupplement, to treat osteoarthritis-related pain. The product is slated for initial availability in the Czech Republic, Germany, Hungary, Italy and Poland, to be marketed by various commercial partners.
CINGAL received CE Mark approval for the present application in...
Anika Therapeutics commenced EU launch of CINGAL®, its third-generation viscosupplement, to treat osteoarthritis-related pain. The product is slated for initial availability in the Czech Republic, Germany, Hungary, Italy and Poland, to be marketed by various commercial partners.
CINGAL received CE Mark approval for the present application in 1Q16.
In addition to Europe, CINGAL is available in Canada. Anika continues to pursue U.S. regulatory approval of the product.
Copy to clipboard 
